This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): SPC2968, EZN-2968, RO7070179
Description: EZN-2968 is a locked nucleic acid antisense oligonucleotide against hypoxia-inducible factor 1a (HIF-1 alpha). HIF-1 alpha is a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy.
Enzon and Santaris
In July 2006, Enzon Pharmaceuticals and Santaris Pharma A/S announced that the companies entered into a collaboration to co-develop and commercialize a series of RNA Antagonists based on Santaris Pharma's LNA (locked nucleic acid) technology.
Under the terms of the agreement, Enzon is licensing two of Santaris Pharma's preclinical development compounds, including EZN-2968. Enzon will have exclusive rights to develop and commercialize it in the U.S. and other non-European territories. Santaris will retain exclusive rights to commercialization in Europe. The companies will share development data for use in their respective territories. Enzon will make an initial up-front payment of $8 million to Santaris Pharma, followed by an additional $3 million upon the successful identification of certain LNA targets and additional payments on the achievement of pre-specified discovery, development and regulatory milestones, representing a potential aggregate...See full deal structure in Biomedtracker
Additional information available to subscribers only: